Small Cancer Player Werewolf Therapeutics' Stock Undervalued: Analyst Says Treatment Platform Underappreciated
Portfolio Pulse from Vandana Singh
Wedbush analysts initiated coverage on Werewolf Therapeutics Inc (NASDAQ:HOWL) with an Outperform rating and a price target of $9. They believe the company's INDUKINE technology, which leverages its proprietary PREDATOR platform for solid tumors, is underappreciated by the market. The analysts see an attractive risk/reward ahead of initial clinical data from lead asset WTX-124, currently in Phase 1 study, in 4Q 2023. As of June 30, 2023, the company had cash and cash equivalents of $137.5 million.
August 24, 2023 | 6:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analysts initiated coverage on Werewolf Therapeutics with an Outperform rating and a price target of $9. They believe the company's INDUKINE technology is underappreciated by the market.
The positive coverage from Wedbush analysts, along with the Outperform rating and a price target of $9, indicates a bullish outlook for Werewolf Therapeutics. The analysts' belief that the company's INDUKINE technology is underappreciated by the market could lead to increased investor interest and potentially a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100